{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:14:14Z","timestamp":1793409254175,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ijantimicag.2022.106707","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T01:33:21Z","timestamp":1672709601000},"page":"106707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020"],"prefix":"10.1016","volume":"61","author":[{"given":"Chih-Hao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Chi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Wang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106707_bib0001","series-title":"Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis","year":"2017"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0002","series-title":"Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in health care facilities","year":"2017"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0003","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106633","article-title":"Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections","volume":"60","author":"Kanj","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0005","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/23744235.2019.1653491","article-title":"Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa \u2013 a pilot Bulgarian study","volume":"51","author":"Savov","year":"2019","journal-title":"Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0006","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jmii.2021.08.012","volume":"55","author":"Liu","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0007","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2217\/fmb-2018-0054","article-title":"Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria","volume":"13","author":"Patel","year":"2018","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jmii.2022.02.001","article-title":"Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms","volume":"55","author":"Sy","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0009","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","article-title":"Critical analysis of antibacterial agents in clinical development","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0010","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC beta-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0011","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijantimicag.2016.01.015","article-title":"Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii","volume":"47","author":"Lob","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02000-21","article-title":"Geographic patterns of carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2015\u20132019","volume":"66","author":"Lee","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0013","series-title":"An antimicrobial susceptibility study to compare the in vitro activity of antimicrobial agents worldwide. Microbiology laboratory study protocol","year":"2018"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0014","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2021"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0015","series-title":"Breakpoint tables for interpretation of MICs and zone diameters, Version 11.0","year":"2022"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0016","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0017","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ijantimicag.2018.01.006","article-title":"Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016)","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0018","series-title":"FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning","year":"2017"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0019","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkn165","article-title":"Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) acinetobacter infections: a review of the scientific evidence","volume":"62","author":"Karageorgopoulos","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0020","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2005.02.013","article-title":"Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline","volume":"25","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0021","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0022","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4103\/0366-6999.201601","article-title":"Trends in drug resistance of Acinetobacter baumannii over a 10-year period: nationwide data from the China Surveillance of Antimicrobial Resistance Program","volume":"130","author":"Gao","year":"2017","journal-title":"Chin Med J"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0023","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/AAC.01727-13","article-title":"Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital","volume":"58","author":"Deng","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0024","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I Randomized Clinical Trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0026","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/jac\/dkab141","article-title":"In vitro activity of imipenem\/relebactam, meropenem\/vaborbactam, ceftazidime\/avibactam, cefepime\/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan","volume":"76","author":"Kuo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0027","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/jcm10051068","article-title":"An update on eight \"new\" antibiotics against multidrug-resistant Gram-negative bacteria","volume":"10","author":"Yusuf","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0028","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jgar.2018.12.001","article-title":"Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: a retrospective matched cohort study","volume":"17","author":"Raz-Pasteur","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0029","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1128\/AAC.01082-16","article-title":"In vitro bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates","volume":"60","author":"Nepka","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0030","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/antibiotics10070880","article-title":"In vitro synergy of colistin in combination with meropenem or tigecycline against carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0031","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1038\/s41598-022-11464-6","article-title":"In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane\/tazobactam against carbapenem-resistant Acinetobacter baumannii","volume":"12","author":"Ju","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0032","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0033","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/1348-0421.12887","article-title":"Current situation of carbapenem-resistant Enterobacteriaceae and acinetobacter in Japan and Southeast Asia","volume":"65","author":"Akeda","year":"2021","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00042-16","article-title":"Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia","volume":"30","author":"Hsu","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1017\/ice.2018.58","article-title":"A systematic review of the burden of multidrug-resistant healthcare-associated infections among intensive care unit patients in Southeast Asia: the rise of multidrug-resistant Acinetobacter baumannii","volume":"39","author":"Teerawattanapong","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0036","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/CMR.00117-13","article-title":"OXA beta-lactamases","volume":"27","author":"Evans","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0037","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1574-6968.2006.00195.x","article-title":"The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii","volume":"258","author":"Turton","year":"2006","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.ijantimicag.2022.106707_bib0038","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/ijmr.IJMR_2085_17","article-title":"Molecular characterization & epidemiology of carbapenem-resistant Acinetobacter baumannii collected across India","volume":"149","author":"Vijayakumar","year":"2019","journal-title":"Indian J Med Res"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922002394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922002394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:44:30Z","timestamp":1760377470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922002394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0924857922002394"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106707","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106707"}}